Bovis calculus sativusは,PKA/CREB/Sirt1/eIF2αシグナル伝達経路を調節することによって,脳卒中の後の認知機能を改善する
Ze-Jun Guo1, Lei Zhang2, Ling-Feng Wang3
1School of Pharmaceutical Sciences, ZheJiang Chinese Medical University, Hangzhou, 310053, China.
Journal of ethnopharmacology
|August 31, 2025
まとめ
Bovis calculus sativus (BCS) は,PKA/ CREB/ Sirt1/ eIF2α経路を通じてシナプス可塑性を高めることで,不全性脳卒中の後の認知機能を改善する. この伝統的な薬は 脳卒中による認知障害の治療に 潜在力を示しています
科学分野:
- 神経科学
- 薬理学について
- 中国 伝統 医学
背景:
- ボビス・カルクルス・サティヴス (BCS) は,熱を浄化し,認知能力を高める性質を持つ伝統的な薬です.
- 認知障害による不全性脳卒中に使用されるが,そのメカニズムは解明する必要がある.
研究 の 目的:
- BCSが脳卒中による認知障害の治療の可能性を調査する.
- シナプス可塑性とPKA/CREB/Sirt1/eIF2α経路を含むメカニズムを探求する.
主な方法:
- ICRマウスにおける全脳性缺血/再注血 (GCI/R) モデルを確立した.
- 行動テストを用いて認知機能を評価し ヒポキャンパスのCA1領域を分析した.
- シナプス可塑性と Western blot 経由によるシグナル伝達に関する重要なタンパク質の表現を定量化した.
主要な成果:
- BCS (10および15 mg/ kg) は認知機能の有意な改善とニューロンの整合性を保ちました.
- PERK/eIF2α経路を抑制しながら,p-PKA,CREB,Sirt1を上調した.
- これは,PSD95とSYN1の発現の増加によって示されたシナプス再構成を促進しました.
結論:
- BCSは,PKA/CREB/Sirt1/eIF2α経路を通じて,海馬のシナプス可塑性を強化する.
- このメカニズムは神経の生存を促進し,脳卒中モデルにおける認知機能を改善します.
- BCSは脳卒中による認知障害の治療薬としての可能性を 示しています
さらに関連する動画
10:32Implantation of Miniosmotic Pumps and Delivery of Tract Tracers to Study Brain Reorganization in Pathophysiological Conditions
Published on: January 18, 2016
14.3K
06:54A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
Published on: June 22, 2022
2.9K
関連する概念動画
01:27Regulation of Stroke Volume
3.5K
The regulation of stroke volume, which is the amount of blood the heart pumps out during each heartbeat, is critical for maintaining a healthy circulatory system. Stroke volume is influenced by three main factors: preload, contractility, and afterload.
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
3.5K
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
445
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
445
01:17Ischemic Heart Disease: Overview
1.4K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.4K